Bristol seeks novelty in TIGIT
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
Astra goes pivotal with CTLA-4
Liver toxicity notwithstanding, volrustomig will start a phase 3 lung cancer study versus Keytruda imminently.
